Quick Answer
OnKure Therapeutics, Inc. reported Net Income Loss of -$59.52 million for the year ending 2025.
- OnKure Therapeutics, Inc. showed a decrease of -13.0% in Net Income Loss from 2024 to 2025.
- This data is from OnKure Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), OnKure Therapeutics, Inc.'s Net Income Loss has declined by 205.8%.
- Historical annual values: Fiscal year 2025: -$59.52 million | Fiscal year 2024: -$52.67 million | Fiscal year 2023: -$35.31 million | Fiscal year 2022: -$51.96 million | Fiscal year 2021: -$39.77 million | Fiscal year 2020: -$19.47 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: